Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

AGILENT TECHNOLOGIES, INC. (A)

As of 2026-11-17 · 11/15 boxes filled from SEC filings and market data

Report price $172.92 (close 2026-11-16); latest close $170.38 (2026-11-20), -1.5% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case +8% · downside -35% · upside +14%

The market is not missing much: at $172.92 the shares trade at 33.9x TTM net income and 26.7x EBITDA, only 5.5% below the 52-week high, on $1.44B of TTM net income, while the reverse DCF needs +12.7% revenue growth a year for a decade against +6.7% delivered in the latest fiscal year and +5.8% to +6.0% core guided. The business is durable, with a 14.6% ROIC against an 8.5% WACC and $1.27B of TTM free cash flow, but the price already pays for that quality. My call is PASS: reward to risk is 0.34 and the cases leave no edge. The downside is $111.30, -35.6%, on -19.0% earnings at a compressed P/E of 26.95x (today 33.9x). The base is $184.65, +6.8%, on a P/E at 36.2x, the peer median P/E. The upside is $193.67, +12.0%, on +12% earnings at today's P/E of 33.9x. A base that returns +6.8% does not compensate for a -35.6% downside.

Key numbers

  • Share price: $170.38
  • Market cap: $48.04B
  • Latest financial period: TTM to Jul 31, 2026
  • Revenue (TTM): $7.37B
  • EV / EBITDA (TTM): 26.3x
  • P/E (TTM): 33.4x
  • FCF yield: 2.6%
  • Price / book: 6.52x
  • Earnings-quality flags (TTM): none flagged
  • EV / FCF (TTM): 39.6x
  • Revenue growth (latest fiscal year): +6.7%
  • ROIC (TTM): 14.6%
  • WACC: 8.5%
  • Economic profit spread: +6.1 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Agilent sells instruments, software, services and consumables across the laboratory workflow, plus specialty CDMO/oligo API capacity. In FY2025 it reported three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets — versus the FY2020 map of life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The November 2024 reorganization moved LC/LCMS into the diagnostics segment, moved chemistries/supplies, lab automation and software into CrossLab, and left GC/GCMS, spectroscopy, vacuum and remarketed instruments in Applied Markets. FY2025 revenue was $6.95B with operating income $1.48B, net income $1.30B and operating cash flow $1.56B; TTM to 2026-07-31 was $7.37B revenue, $1.64B operating income, $1.44B net income and $1.61B operating cash flow.

  2. ○ 2. Competitive advantage

    The record shows a durable but not extraordinary advantage: operating margin computed from the six-year XBRL stayed between 15.8% (FY2020) and 23.6% (FY2022), was 21.3% in FY2025 and 22.3% on the TTM to 2026-07-31, and revenue fell in only one of the five year-over-year steps (FY2024, -4.7%). Cash backs it up - operating cash flow never fell below $921.0M in the six years and free cash flow after capex was $1.15B in FY2025 and $1.27B on the TTM. Against that, the 10-K describes an intensely competitive, fast-cycle life-sciences market where pricing pressure can hit a cost base that is largely fixed, and demand sits on customers' R&D and government funding budgets; capex has also climbed from $119.0M (FY2020) to $407.0M (FY2025). No source names a single competitor or gives market share.

  3. ✓ 3. 10-Q takeaways

    Q3 FY2026 (quarter ended 2026-07-31) was an up-quarter: revenue $1,878M, +8% reported and +7.3% core, with GAAP operating margin 23.6% (+290bp y/y) and non-GAAP 28.3%, helped by an approximately 1 percentage point net benefit from tariff refunds. All three segments grew (LDG +11%, ACG +6%, AMG +7%) and the company raised FY2026 revenue, margin and non-GAAP EPS guidance, while Q4 guidance excludes any future tariff refunds. Cash generation held up (nine-month operating cash flow $1,064M vs $1,014M), inventory and goodwill rose with the $950M Biocare deal, and buybacks continued under the 2024 program with $1,654M left at July 31, 2026. One-offs to keep separate: a $15M restructuring charge in Q3, tariff refunds in the margin, and a prior-year $28M tax-reserve release that flattered Q3 FY2025's 8.2% tax rate.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans